DK2276501T3 - Fremgangsmåder og sammensætninger til genetisk og retinal sygdom - Google Patents
Fremgangsmåder og sammensætninger til genetisk og retinal sygdom Download PDFInfo
- Publication number
- DK2276501T3 DK2276501T3 DK09719985.5T DK09719985T DK2276501T3 DK 2276501 T3 DK2276501 T3 DK 2276501T3 DK 09719985 T DK09719985 T DK 09719985T DK 2276501 T3 DK2276501 T3 DK 2276501T3
- Authority
- DK
- Denmark
- Prior art keywords
- norrin
- protein
- cell
- compound
- retinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
1. Norrin-forbindelse til anvendelse ved behandling af en patologisk tilstand i retina, hvor Norrin-forbindelsen er en nukleotidsekvens, der koder for et Norrin-protein, en celle, som er transficeret med en nukleotidsekvens, der koder for et Norrin-protein, og omfatter den pågældende nukleotidsekvens, eller et Norrin-protein, hvor Norrin-proteinet er valgt fra gruppen bestående af et polypeptid med sekvensen ifølge SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, et oligomert kompleks, som omfatter et Norrin-protein, og en muteret form af et Norrin-protein, hvor den muterede form er valgt fra gruppen bestående af R64E-mutanten, T27A-, S28A- og S29A-mutanten; P36A-, R37A- og R38A-mutanten og H127A-, E129A- og E130A-mutanten af polypeptidet ifølge SEQ ID NO: 1, hvor den retinale sygdom er valgt fra gruppen bestående af vitreoretinopati, præmaturitetsretinopati og familiær ekssudativ vitreoretinopati.
2. Norrin-forbindelse til anvendelse ifølge krav 1, hvor nukleotidsekvensen, der koder for et Norrin-protein, er en genoverførselsvektor.
3. Norrin-forbindelse til anvendelse ifølge et hvilket som helst af de foregående krav, hvor forbindelsen skal administreres intraokulært, ved topisk applikation i øjet, ved intraokulær injektion, lokalt ved indføring eller injektion i vævet omkring øjet, systemisk ad oral vej, eller ved subkutan, intravenøs eller intramuskulær injektion.
4. Norrin-forbindelse til anvendelse ifølge krav 3, hvor den intraokulære injektion sker i corpus vitreum-rummet eller subretinalt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3671708P | 2008-03-14 | 2008-03-14 | |
| PCT/US2009/037792 WO2009114878A2 (en) | 2008-03-14 | 2009-03-20 | Methods and compositions for genetic and retinal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2276501T3 true DK2276501T3 (da) | 2017-03-20 |
Family
ID=41065889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09719985.5T DK2276501T3 (da) | 2008-03-14 | 2009-03-20 | Fremgangsmåder og sammensætninger til genetisk og retinal sygdom |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2276501B1 (da) |
| DK (1) | DK2276501T3 (da) |
| WO (1) | WO2009114878A2 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367564A1 (en) * | 2008-12-22 | 2011-09-28 | Universität Regensburg | Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| EP2968452A4 (en) * | 2013-03-15 | 2016-10-05 | Michael Thomas Trese | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES |
| US10202429B2 (en) | 2015-06-08 | 2019-02-12 | Retinal Solutions Llc | Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema |
| US10206978B2 (en) | 2015-06-08 | 2019-02-19 | Retinal Solutions Llc | Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema |
| US10669321B2 (en) | 2015-06-08 | 2020-06-02 | Retinal Solutions Llc | Retinal capillary regeneration with synthetic norrin protein |
| CN111926021B (zh) * | 2020-07-29 | 2024-06-21 | 武汉纽福斯生物科技有限公司 | 重组人norrin胱氨酸结生长因子表达载体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667968A (en) * | 1989-08-30 | 1997-09-16 | Regeneron Pharmaceuticals, Inc. | Prevention of retinal injury and degeneration by specific factors |
| CA2346262A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
| AU2002346611A1 (en) | 2001-12-03 | 2003-06-17 | The Regents Of The University Of California | Expression of glial-derived neurotrophic factor for treatment of diseases of the eye |
| US20040086572A1 (en) | 2002-07-17 | 2004-05-06 | Dailey James P. | Delivery of therapeutic agent affixed to magnetic particle |
| US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20070154465A1 (en) | 2005-12-30 | 2007-07-05 | Alexandar Kharazi | Stem cell therapy for retinal disease |
-
2009
- 2009-03-20 EP EP09719985.5A patent/EP2276501B1/en not_active Not-in-force
- 2009-03-20 WO PCT/US2009/037792 patent/WO2009114878A2/en not_active Ceased
- 2009-03-20 DK DK09719985.5T patent/DK2276501T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009114878A3 (en) | 2009-12-03 |
| EP2276501A4 (en) | 2011-06-01 |
| EP2276501B1 (en) | 2017-02-15 |
| WO2009114878A2 (en) | 2009-09-17 |
| EP2276501A2 (en) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9504649B2 (en) | Method and compositions for genetic and retinal disease | |
| RU2734678C2 (ru) | Генетическая конструкция | |
| Kauper et al. | Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases | |
| DK2276501T3 (da) | Fremgangsmåder og sammensætninger til genetisk og retinal sygdom | |
| JP2019520788A (ja) | 抗Ｒｙｋ抗体およびその使用方法 | |
| US9914782B2 (en) | Methods for preserving the viability of retinal ganglion cells in patients with glaucoma by an anti-TNF receptor 2 (anti-TNFR2) antibody | |
| US11198714B2 (en) | Synthetic truncated norrin protein | |
| CA2970748C (en) | Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration | |
| CN113645994A (zh) | 使用色素上皮衍生因子(pedf)治疗疾病的方法 | |
| EP2491143B1 (en) | Methods and compositions for diagnosis and treatment of genetic and retinal disease | |
| JP2023027172A (ja) | ノリン誘発性の遺伝子発現および疾患を処置するためのその使用 | |
| Trofimova | Molecular mechanisms of retina pathology and ways of its correction | |
| US20160331807A1 (en) | Therapeutic use of vegfr-3 ligands | |
| Hu | Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Delayed Cell-Based Intravitreal Co-Therapy with Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor | |
| WO2021142410A1 (en) | Neural regeneration with synthetic protein administration | |
| CN116437898A (zh) | 包含plvap作为活性成分的用于预防或治疗视网膜或脉络膜疾病的药物组合物 | |
| HK1069767B (en) | Methods for inhibiting ocular processes |